Publications by authors named "Michael D Tsifansky"

Claim this Profile
T
Treatment of chronic relapsing urinary tract infection with antibiotics selected by AtbFinder.
George V Tetz, Kristina M Kardava, Maria F Vecherkovskaya, Michael D Tsifansky, Victor V Tetz

Urol Case Rep· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanocapsules modify membrane interaction of polymyxin B to enable safe systemic therapy of Gram-negative sepsis.
Simseok A Yuk, Hyungjun Kim, Nader S Abutaleb, Alexandra M Dieterly, Maie S Taha, Michael D Tsifansky

Sci Adv· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
V/Q-SPECT Scintigraphy in Pulmonary Hypertension: Predictor of Mortality Versus Trigger for Transplant, A British Versus American Perspective.
Marc Ovadia, Michael D Tsifansky

JACC Cardiovasc Imaging· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in nanomedicine for sepsis treatment.
Simseok A Yuk, Diego A Sanchez-Rodriguez, Michael D Tsifansky, Yoon Yeo

Ther Deliv· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Succinylated chitosan derivative has local protective effects on intestinal inflammation.
Hyesun Hyun, Seika Hashimoto-Hill, Myunghoo Kim, Michael D Tsifansky, Chang H Kim

ACS Biomater Sci Eng· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zwitterionic chitosan for the systemic treatment of sepsis.
Eun Jung Cho, Kyung-Oh Doh, Jinho Park, Hyesun Hyun, Erin M Wilson, Michael D Tsifansky

Sci Rep· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
Yan Yang, Michael D Tsifansky, Sooyoung Shin, Qingnuo Lin, Yoon Yeo

Biotechnol Bioeng· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.
Basma M Ibrahim, Michael D Tsifansky, Yan Yang, Yoon Yeo

Expert Opin Drug Deliv· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.
Yan Yang, Michael D Tsifansky, Chia-Jung Wu, Hae In Yang, Gudrun Schmidt

Pharm Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of highly porous large PLGA microparticles for pulmonary drug delivery.
Yan Yang, Nimisha Bajaj, Peisheng Xu, Kimberly Ohn, Michael D Tsifansky

Biomaterials· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microparticles for inhalational delivery of antipseudomonal antibiotics.
Michael D Tsifansky, Yoon Yeo, Oleg V Evgenov, Evangelia Bellas, John Benjamin

AAPS J· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexmedetomidine: do we know enough?
Michael D Tsifansky, Carol G Schmitt, Ricardo A Muñoz

Pediatr Crit Care Med· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis